Press release -
Attana highlighted in Today in America with Terry Bradshaw
The program aims to inform the general public about the complexities of the human body and to emphasize the challenges of the drug development process. Furthermore, the program presents a solution interesting for scientists and decision makers working within the field of drug development, showing how it is possible to save both time and money when developing drugs. Having access to biologically relevant information, i.e. experimental data that mimics the conditions of the human body as closely as possible is crucial for finding the best new drug candidate. The Attana Cell 200 biosensor has the unique ability to measure molecular interactions directly on human cells and provides critical data to the drug development process.
For every new drug on the market, thousands of candidate molecules have failed during the research and test phases. The later in the process a candidate fails, the more time and money is spent on it. When a candidate reaches the clinical phase with human test subjects, the costs increase significantly. Besides the fact that a faulty drug increases costs, it also has the potential to harm the test persons. Therefore, a drug that is thoroughly investigated before it enters clinical trials risks less harmful consequences.
Attana’s technology provides biologically relevant information that enables selection of the good candidates and sorts out the unsuitable ones earlier in the drug development process. Biologically relevant information is crucial for the drug development process- it helps save both time and money and in finding the best new drug candidate.
See a preview of the show here visit our web page at www.attana.com. If you want to find out more about Attana and our products, send an email to info@attana.com.
The segment will be aired on March 5th, nationally in North America on Fox Business Network (4:00 PM ET, 3:00 PM CT, 2:00 PM MT, 1:00 PM PT) and on March 11th on CNN Headline News (Comcast Cable, Seattle- Tacoma, 2:24 pm, 3:24 pm, 5:54 pm, 6:24 pm). The Today in America program is an independent production hence not a Fox Business Network or CNN Headline News production.
Addtional airtimes:
2nd April, 1.30 pm- WEMZ-TV -Philadelphia-Allentown-Bethlehem-Reading
3rd Aprill, 6.30 am -PCNC - Pittsburgh Cable News Network
9th April,1.30 pm- WEMZ-TV -Philadelphia-Allentown-Bethlehem-Reading
1oth April,6.30 am -PCNC - Pittsburgh Cable News Network
16th April, 1.30 pm- WEMZ-TV -Philadelphia-Allentown-Bethlehem-Reading
17th April,6.30 am -PCNC - Pittsburgh Cable News Network
23rd April, 1.30 pm- WEMZ-TV -Philadelphia-Allentown-Bethlehem-Reading
24th April,6.30 am -PCNC - Pittsburgh Cable News Network
30th April, 1.30 pm- WEMZ-TV -Philadelphia-Allentown-Bethlehem-Reading
Topics
- Medical research
Categories
- tecan
- attana cell 200
- biosensor
- terry bradshaw
- attana
- today in america
About Attana AB
Founded in 2002, based in Stockholm, Sweden, Attana AB develops biosensors for the pharmaceutical, diagnostic and academic society worldwide. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to increasing the success during clinical trials by providing the life science community with biologically relevant information. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
For more information you may contact marketing manager at Attana: Gabriela Suhoschi:gabriela.suhoschi@attana.com; Tel: +46 8 674 57 12.
In North America, Attana is represented by Tecan US, Inc. For more information about Tecan and Attana in North America you may contact Dr. Simon Fogarty at Tecan, Director of Application Science; Tel: 1 919 599 4448, simon.fogarty@tecan.com.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
